
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius ... Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok(R), an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.03 | -1.88679245283 | 1.59 | 1.7 | 1.475 | 53667 | 1.56956879 | CS |
4 | -0.63 | -28.7671232877 | 2.19 | 2.19 | 1.47 | 93700 | 1.70320893 | CS |
12 | -1.59 | -50.4761904762 | 3.15 | 5.95 | 1.47 | 150926 | 2.83391076 | CS |
26 | -12.69 | -89.0526315789 | 14.25 | 15.25 | 1.47 | 2249753 | 4.88814316 | CS |
52 | -16.74 | -91.4754098361 | 18.3 | 26.75 | 1.47 | 1976531 | 10.8736886 | CS |
156 | -39.94 | -96.2409638554 | 41.5 | 50.25 | 1.47 | 1350220 | 19.69673322 | CS |
260 | -10.94 | -87.52 | 12.5 | 114 | 1.47 | 2684002 | 41.63033147 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions